Pasithea Therapeutics
KTTA
26 hedge funds and large institutions have $7.6M invested in Pasithea Therapeutics in 2026 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 5 closing their positions.
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
16% more capital inflows, than outflows
Capital inflows: $2.36M | Capital outflows: $2.03M
4% more funds holding
Funds holding: 25 → 26 (+1)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
21.17% less ownership
Funds ownership: 67.31% → 46.14% (-21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stonepine Capital Management
Bend,
Oregon
|
+$288K |
| 2 |
AdvisorShares Investments
Bethesda,
Maryland
|
+$112K |
| 3 |
Jane Street
New York
|
+$71.9K |
| 4 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$64.6K |
| 5 |
HRT Financial
New York
|
+$50.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.06M |
| 2 |
Squadron Capital Management
Westmont,
Illinois
|
-$515K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$244K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$94.6K |
| 5 |
Vivo Capital
Palo Alto,
California
|
-$46.6K |
KTTA Hedge Fund Activity: Q3 2026 in Review
26 of the 8,184 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q3 2026, worth a combined $7.6M — down 12% from $8.66M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new KTTA positions and 5 closed out — a net gain of 2 holders — while 5 added to existing stakes and 6 trimmed.
The largest buyer was Stonepine Capital Management, adding an estimated $288K. The largest seller was Opaleye Management, exiting entirely with an estimated $1.06M sold.
- 26 institutional investors held Pasithea Therapeutics (KTTA) as of Q3 2026, up from 25 in Q2 2026.
- Funds reported $7.6M of Pasithea Therapeutics stock for Q3 2026, down 12% quarter-over-quarter.
- 7 funds opened new Pasithea Therapeutics positions in Q3 2026 and 5 closed out, a net change of +2 holders.
- The largest Pasithea Therapeutics buyer in Q3 2026 was Stonepine Capital Management, an estimated $288K added.
- The largest Pasithea Therapeutics seller in Q3 2026 was Opaleye Management, an estimated $1.06M sold.
Based on aggregated 13F filings for Q3 2026.